Sustained-Release Innovation for Wet AMD & DR with an Intravitreal Implant
Time: 3:00 pm
day: Day One
Details:
- Discuss the limitations of current treatments for retinal diseases like wet AMD and Diabetic Retinopathy, which require frequent intravitreal injections, leading to increased risk of complications and patient discomfort
- Explore the advantages of AXPAXLI (OTX-TKI), a bioresorbable hydrogel implant designed to provide sustained release of axitinib, offering a broad antiangiogenic effect with the potential to extend treatment intervals to 6 months or longer
- Highlight the innovative product design, including the small fiber format, which aims to minimize visual impact and eliminate the need for preservatives, potentially improving patient outcomes and adherence
